MSH2 and cancer: Panagopoulou et al. established a cfDNA methylation panel of five cancer-related genes (KLK10, SOX17, WNT5A, MSH2, and GATA3) and found that increased methylation of three or more and four or more genes (KLK10, SOX17, WNT5A, and MSH2) significantly correlated to OS (p = 0.042, 0.043, and 0.048) and the absence of pharmacotherapy response (p = 0.002), respectively.